Immunoediting Removes High-Quality Neoantigens in Pancreatic Cancer

Area of Science:

• Oncology
• Immunology
• Genomics

Background:

• Pancreatic cancer is a leading cause of cancer-related mortality.
• Long-term survival in pancreatic cancer is rare, and understanding tumor recurrence is critical.
• Neoantigens are crucial targets for anti-tumor immunity.

Purpose of the Study:

• To investigate the neoantigen landscape in recurrent tumors from long-term pancreatic cancer survivors.
• To compare neoantigen quality between primary and recurrent tumors.

Main Methods:

• Whole exome sequencing of primary and recurrent tumor samples.
• Bioinformatic analysis to identify and quantify neoantigens.
• Assessment of neoantigen quality based on predicted binding affinity and immunogenicity.

Main Results:

• Recurrent tumors from long-term survivors exhibited a significantly lower number of high-quality neoantigens compared to primary tumors.
• The identified neoantigens in recurrent tumors showed reduced predicted immunogenicity.
• Specific mutations associated with immune evasion were observed in recurrent lesions.

Conclusions:

• The paucity of high-quality neoantigens may contribute to tumor recurrence and immune escape in long-term pancreatic cancer survivors.
• Therapeutic strategies targeting neoantigens may need to consider the evolving tumor landscape during recurrence.